Targeting the epidermal growth factor receptor: An important incremental step in the battle against colorectal cancer

被引：36

作者：

Ellis, LM

Hoff, PM

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA

[3] Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 07期

关键词：

D O I：

10.1200/JCO.2004.01.971

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1177 / 1179

页数：3

共 12 条

[1]

Arteaga CL, 2001, J CLIN ONCOL, V19, p32S

[2] Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines [J].

Bancroft, CC ;

Chen, Z ;

Yeh, J ;

Sunwoo, JB ;

Yeh, NT ;

Jackson, S ;

Jackson, C ;

Van Waes, C .

INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (04) :538-548

[3] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].

Baselga, J ;

Pfister, D ;

Cooper, MR ;

Cohen, R ;

Burtness, B ;

Bos, M ;

D'Andrea, G ;

Seidman, A ;

Norton, L ;

Gunnett, K ;

Falcey, J ;

Anderson, V ;

Waksal, H ;

Mendelsohn, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914

[4] Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance [J].

Busse, D ;

Yakes, FM ;

Lenferink, AEG ;

Arteaga, CL .

SEMINARS IN ONCOLOGY, 2001, 28 (05) :47-55

[5]

CUNINGHAM D, 2003, P AN M AM SOC CLIN, V22, P252

[6]

Hill R P, 2001, Novartis Found Symp, V240, P154

[7] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J].

Kabbinavar, F ;

Hurwitz, HI ;

Fehrenbacher, L ;

Meropol, NJ ;

Novotny, WF ;

Lieberman, G ;

Griffing, S ;

Bergsland, E .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :60-65

[8] Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [J].

Mendelsohn, J ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2787-2799

[9] Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial [J].

Rothenberg, ML ;

Oza, AM ;

Bigelow, RH ;

Berlin, JD ;

Marshall, JL ;

Ramanathan, RK ;

Hart, LL ;

Gupta, S ;

Garay, CA ;

Burger, BG ;

Le Bail, N ;

Haller, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2059-2069

[10]

SALTZ L, 2001, 37 ANN M AM SOC CL 1, V20, P3

← 1 2 →